4-[(2-氨基苯基)磺酰基]吗啉 | 208643-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[(2-氨基苯基)磺酰基]吗啉
• 英文名称: 2‐(morpholine‐4‐sulfonyl)aniline
• 英文别名: 2-(morpholine-4-sulfonyl)aniline；2-(morpholinosulfonyl)aniline；2-(Morpholin-4-ylsulfonyl)aniline；2-morpholin-4-ylsulfonylaniline
• CAS: 208643-03-2
• 化学式: C₁₀H₁₄N₂O₃S
• mdl: MFCD04035364
• 分子量: 242.299
• InChiKey: WLPZGLWVUUJJTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  81
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Morpholin-4-ylsulfonyl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Morpholin-4-ylsulfonyl)aniline
CAS number: 208643-03-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H14N2O3S
Molecular weight: 242.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  三光气 、 4-[(2-氨基苯基)磺酰基]吗啉 在 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以76%的产率得到1,3-bis(2-(morpholinosulfonyl)phenyl)urea
  参考文献：
  名称：

  Antischistosomal activity of N,N′-arylurea analogs against Schistosoma japonicum

  摘要：

  Although the antischistosomal activities of N,N'-arylurea analogs were reported, systematic structure-activity relationships have not been conducted. In this Letter, we reported the design, synthesis and evaluation of 45 N,N'-arylurea analogs. Among these prepared compounds, 13 compounds were urea linker modified and 32 were N,N'-arylurea derivatives. The activity evaluation revealed 12 analogs exhibited IC50 values lower than 22.6 mu M, and 7 of them had IC50 less than 10 mu M against the juvenile Schistosoma japonicum in vitro. Their worm killing potency was even higher against adult worm. Unfortunately, low to moderate worm burden reduction of 0-33.4% was recorded after administration of a single oral dose of 200 mg/kg or 400 mg/kg to mice harboring S. japonicum. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2016.01.075
• 作为产物：
  描述：

  4-(2-硝基苯基磺酰基)吗啉 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 生成 4-[(2-氨基苯基)磺酰基]吗啉
  参考文献：
  名称：

  酰胺和磺酰胺取代的N-芳基6-氨基喹喔啉类化合物作为具有改进的理化性质的PFKFB3抑制剂的合成。

  摘要：

  在肿瘤学中，“ Warburg效应”描述了癌细胞中糖酵解产生的能量增加。普遍存在且缺氧诱导的6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶3（PFKFB3）在通过产生果糖-2,6-二磷酸（F-2,6- BP），一种限制糖酵解速率的磷酸果糖激酶PFK-1的有效活化剂。合成了一系列基于N-芳基6-氨基喹喔啉骨架的酰胺和磺酰胺衍生物，并在体外通过生化测定以及在HCT116细胞中测试了它们对PFKFB3的抑制作用。羧酰胺系列显示出令人满意的动力学溶解度和代谢稳定性，并且在该类别中，已鉴定出具有低纳摩尔活性的强效铅化合物，并具有适合进一步体内评估的合适特征。

  DOI：

  10.1016/j.bmcl.2018.12.034

文献信息

• [EN] SUBSTITUTED QUINOXALINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOXALINE SUBSTITUÉS
  申请人：SELVITA S A

  公开号：WO2016180537A1

  公开（公告）日：2016-11-17

  The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

  这项发明涉及取代喹喔啉衍生物。这些化合物对预防和/或治疗包括过度增殖性疾病在内的多种医疗状况具有用处。
• BRIDGED PHENANTHRIDINES
  申请人：Ralbovsky Janet L.

  公开号：US20080214537A1

  公开（公告）日：2008-09-04

  Bridged phenanthridine compounds having the structure of formula I or of formula II are provided: These compounds are useful as cannabinoid receptor ligands and can be prepared as pharmaceutical compositions for the prophylaxis or treatment of a variety of diseases, disorders and conditions including inflammatory pain, visceral pain, postoperative pain, cancer pain, neuropathic pain, musculoskeletal pain, dysmenorrhea, menstrual pain, migraine, headache as well as inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, psoriasis, eczema, multiple sclerosis, diabetes and thyroiditis. The compounds can also be used in the treatment of skin disorders, lung disorders, ophthalmic disorders, gastrointestinal disorders, cardiovascular disorders, as well as neurodegenerative, neuroinflammatory and certain psychiatric disorders.

  提供具有结构式I或结构式II的桥联菲啰啉化合物：这些化合物可用作大麻素受体配体，并可制备为用于预防或治疗各种疾病、紊乱和症状的药物组合物，包括炎症性疼痛、内脏疼痛、术后疼痛、癌症疼痛、神经病性疼痛、肌肉骨骼疼痛、痛经、月经疼痛、偏头痛、头痛以及风湿性关节炎、系统性红斑狼疮、克罗恩病、牛皮癣、湿疹、多发性硬化症、糖尿病和甲状腺炎等炎症性疾病。这些化合物还可用于治疗皮肤疾病、肺部疾病、眼科疾病、胃肠疾病、心血管疾病，以及神经退行性疾病、神经炎症性疾病和某些精神疾病。
• Aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20010037039A1

  公开（公告）日：2001-11-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 —R 4 , R 6 —R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula . The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  描述了氨基胍和烷氧基胍化合物，包括式子：1中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在规范中给出，以及其水合物、溶剂化合物或药物可接受的盐，这些化合物抑制蛋白酶酶，如凝血酶。还描述了制备公式化合物的方法。本发明的新型化合物是蛋白酶的有效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性地抑制凝血酶表现出抗血栓活性，或者是用于制备具有抗血栓活性的化合物的中间体。本发明包括一种组合物，用于抑制哺乳动物中的血小板丢失、抑制血小板聚集的形成、抑制纤维蛋白的形成、抑制血栓形成和抑制栓塞形成，包括本发明中的化合物和药物可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液采集、血液循环和血液储存的设备中使用的材料中，如导管、血液透析机、血液采集注射器和管、血液管路和支架。
• Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040002539A1

  公开（公告）日：2004-01-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 -R 4 , R 6 -R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula L The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  本发明涉及氨基胍和烷氧基胍化合物，包括以下式子的化合物：1其中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在说明书中给出，以及其水合物、溶剂合物或药学上可接受的盐，其抑制蛋白酶如凝血酶。还描述了制备式L化合物的方法。本发明的新化合物是蛋白酶的强力抑制剂，尤其是类胰蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种用于抑制哺乳动物体内血小板丧失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物，其中包括本发明中的化合物和药学上可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理链接到用于血液收集、血液循环和血液储存的设备制造中使用的材料中，如导管、血液透析机、血液采集注射器和管道、血液输送管和支架等。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。